[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nantes University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":616},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,179,0,25,[9,50,77,104,130,153,180,208,235,256,276,294,317,338,367,385,414,437,459,483,506,532,553,573,593],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053379","phase-3-lidocaine-for-opioid-sparing-in-vaso-occlusive-crisis-of-sickle-cell-disease-100053379",false,"NCT07274254","Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease","LidoVOC","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Known sickle cell disease with an SS, SC, Sβ, or Sβ+ genotype\n* Patient admitted to the Intensive Care Unit for Vaso-Occlusive Crisis and\u002For ACS as the main reason for admission:\n\n  * Vaso-Occlusive Crisis defined by acute pain or tenderness, affecting at least one part of the body, including limbs, ribs, sternum, head (skull), spine, and\u002For pelvis, not attributable to other causes\n  * Acute Chest Syndrome defined by the association of clinical respiratory sign(s): dyspnea and\u002For chest pain and\u002For auscultatory abnormality (crepitants and\u002For bronchial breathing) with a new pulmonary infiltrate on chest X-ray, thoracic CT-scan, or lung ultrasound.\n* Treatment with parenteral morphine or oxycodone started less than 72 hours prior to inclusion\n* Patient or next of kin informed about the study and having consented to the participation of the patient in the study. If patient is no competent and no next of kin can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the Intensive Care Unit physician, in compliance with French law.\n* French speaking\n* Patient with health care insurance\n\nExclusion Criteria:\n\n* Pregnant women or nursing mothers; Women of child bearing potential will be tested for pregnancy before inclusion\n* Patients under guardianship, curatorship or under legal protection\n* Prisoners or subjects who are involuntarily incarcerated\n* Sickle Cell Disease acute complication other than Vaso-Occlusive Crisis or Acute Chest Syndrome as the main reason for admission:\n\npriapism, stroke, acute splenic sequestration, acute hepatic sequestration, bone marrow necrosis…\n\n* Patients wearing a lidocaine-medicated plaster at the time of screening for inclusion\n* Known or assumed hypersensitivity to lidocaine hydrochloride, other local anaesthetics (e.g., bupivacaine or ropivacaine) or an excipient\n* Patients treated with anti-arhythmic drugs known to induce torsade de pointe.\n* Patients on chronic or occasional treatment with drugs that interact with the 3A cytochrome isoenzymes (CYP3A) and\u002For 1A2 cytochrome isoenzymes (CYP1A2)\n* Patients with recurrent porphyria, porphyria in remission, or known asymptomatic carriage of gene mutations responsible for porphyria\n* Epileptic patients\n* Hypovolemic shock or shock of other cause at screening for inclusion\n* Known atrioventricular block, QT prolongation or other heart conduction disorder or heart failure\n* Chronic respiratory failure with long term non invasive ventilation (excluding Continuous Positive Air way pressure), or long term oxygen therapy at home\n* Acute Respiratory Distress Syndrome according to The 2012 Berlin definition\n* Acute or Chronic liver failure with MELD \\> 19 according to CKD-EPI\n* Acute or Chronic kidney failure with clearance \\\u003C30mL\u002Fmin\u002Fm2\n* Body weight \\\u003C40kg and \\>120kg\n* Prior inclusion in the study in the last 3 months\n* Patient under invasive mechanical ventilation\n* Altered consciousness with Glasgow coma scale \\\u003C13","ALL","18 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of the study is to determine whether adding lidocaine to standard of care in pain management during severe vaso-occlusive crisis has an effect on the cumulative opioid consumption expressed as morphine milligram equivalent.",[27],"Vaso-Occlusive Pain Episode in Sickle Cell Disease",[29,30,31,32,33,34,35,36],"Sickle Cell disease","Sickle Cell Syndrome","Vaso-occlusive crisis","Acute Chest Syndrome","Painful crisis","Pain management","Opioid sparing","Lidocaine","RECRUITING","2026-07-09",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2026-07-03",{"date":45,"type":21},"2028-08-03",{"name":47,"class":48},"Nantes University Hospital","OTHER",11,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100053653","phase-3-evaluation-of-the-analgesic-effect-of-intramyometrial-botulinum-toxin-injection-via-hysteroscopy-in-pelvic-pain-suggestive-of-dysmenorrhea-100053653","NCT06995287","Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea","Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea: A Prospective, Multicenter, Double-Blind, Randomized Placebo-Controlled Study.","HYSTEROXINE","Inclusion Criteria:\n\n* Adult women who are not menopausal,\n* Presenting with:\n* Either severe primary dysmenorrhea, defined by an average pain intensity (VAS) ≥ 6\u002F10 over the last 3 months at the inclusion visit,\n* Or, in cases of amenorrhea under hormonal treatment, severe chronic pelvic pain (average VAS ≥ 6\u002F10 over the last 3 months), described as cramp-like, localized in the pelvic region, and similar to the initial dysmenorrhea pain.\n* Having failed optimal first-line medical treatment combining hormonal therapy and appropriate analgesics (Level I and II analgesics, and NSAIDs),\n* Having undergone a pelvic MRI within 1 year prior to the randomization visit that shows no evidence of deep infiltrating endometriosis or endometrioma, following systematic review by radiologists from the expert center managing the patient (if the pelvic MRI is deemed of insufficient quality for interpretation, a new MRI will be performed at the center),\n* Using a highly effective method of contraception (failure rate \\\u003C1%) for the entire duration of the follow-up period. Highly effective contraception methods are defined as one of the following: combined hormonal contraception (containing estrogen and progestin) with ovulation inhibition (oral, vaginal, or transdermal), progestin-only hormonal contraception with ovulation inhibition (oral, injectable, or implantable), intrauterine device (IUD), intrauterine hormonal system (IUS), condoms, bilateral tubal occlusion, vasectomized partner, or sexual abstinence,\n* Having a negative urine pregnancy test on the day of the procedure,\n* Having signed the informed consent form for the study at the M-1 visit.\n\nExclusion Criteria:\n\n* Pregnant or planning a pregnancy during the entire study period,\n* Currently breastfeeding,\n* Refusal to use effective contraception during the study and for 6 months after its completion,\n* Contraindications to botulinum toxin, including:\n* Generalized disorders of muscular activity (e.g., myasthenia gravis, Lambert-Eaton syndrome),\n* Ongoing treatment with aminoglycosides, peripheral muscle relaxants, or amino-4-quinolines,\n* Hypersensitivity to the active substance, human albumin, or sucrose,\n* Bleeding disorders or current treatment with anticoagulants,\n* Ongoing vaginal or upper genital tract infection,\n* Participation in another interventional clinical trial,\n* Inability to cooperate or understand the study requirements in a way that would allow strict adherence to the protocol,\n* Subject to legal protection measures (e.g., guardianship, curatorship, or judicial protection),\n* Not affiliated with the French social security system,\n* Unable to access the internet to complete questionnaires at Month 1 and Month 6.","FEMALE",{"count":60,"type":21},222,[24],"The objective of the study is to evaluate the global impression of improvement at 3 months following intramyometrial botulinum toxin injections via hysteroscopy in women with severe primary dysmenorrhea who have failed first-line medical treatment, compared to intramyometrial placebo injections.",[64,65],"Primary Dysmenorrhea","Chronic Pelvic Pain",[67,68,69],"Primary dysmenorrhea","injection","Botulimum toxin, Type A",{"date":40,"type":41},{"date":72,"type":41},"2026-02-09",{"date":74,"type":21},"2028-09-09",{"name":47,"class":48},8,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100635219","phase-2-exploratory-study-evaluating-the-relevance-of-68gaga-fapi-46-for-staging-and-identifying-progressing-patients-with-transthyretin-cardiac-amyloidosis-100635219","NCT07549841","Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis","FAPICAM","Inclusion Criteria:\n\n* Men or women ≥ 18 years\n* Definite ATTR-CM diagnosis based on the 2021 ESC expert consensus\n* Written and signed informed consent (obtained on the screening day at the latest and before any investigation)\n* Affiliation with French social security system or beneficiary from such system\n* Women must meet one of the following criteria at the time of inclusion:\n\n  * present a negative pregnancy test (blood test) before the injection of \\[68Ga\\]Ga-FAPI-46 and use highly1 effective contraceptive measures for a duration of 6 months after the PET with \\[68Ga\\]Ga-FAPI-46;\n  * or be post-menopausal (aged over 50 with amenorrhea for at least 12 months after stopping all exogenous hormone treatments);\n  * or (if under 50 years of age) have been in amenorrhea for at least 12 months after stopping exogenous hormone treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels corresponding to post-menopausal levels;\n  * or have undergone irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (this operation must be documented);\n* Male patients will be required to use male contraception (condoms) for a duration of 3 months after the PET;\n* Women partners will be required to use an acceptable2 contraceptive measure (as they will not receive the trial drug) for a duration of 3 months after the PET;\n* Male partners will be required to use male contraception (condoms) for a duration of 6 months after the PET.\n\nExclusion Criteria:\n\n* History of Myocardial infarction or myocarditis\n* Severe aortic stenosis\n* Current or prior participation in a clinical trial evaluating a TTR-targeted gene-silencing therapy (TTR= transthyretin) or an amyloid-depleting treatment for cardiac transthyretin amyloidosis (ATTR-CM).\n* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Women who are pregnant or breastfeeding. A serum pregnancy test will be performed at the start of the study and within 48 hours prior to PET for all female subjects of childbearing potential.\n* Patient under guardianship or trusteeship.\n* Patient under judicial protection.\n* Patient unable to understand spoken or written French\n* Known hypersensitivity to gallium-68, to any excipient or derivative",{"count":85,"type":21},40,[87],"PHASE2","Transthyretin cardiac amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by amyloid fibril deposition, leading to heart failure and arrhythmias. Despite advances in diagnosis, the disease remains commonly unrecognized and presents heterogeneously. Recent therapies targeting transthyretin stabilization and gene silencing have improved outcomes, but current staging systems based on biological and functional markers have limited ability to guide treatment.\n\nImaging techniques such as cardiac magnetic resonance (CMR) provide tissue characterization, but noninvasive molecular imaging of myocardial fibrotic activity remains limited. Positron emission tomography (PET) tracers targeting fibroblast activation protein (FAPI), labeled with gallium-68 (68Ga), offer a promising approach to detect and quantify fibroblast activity associated with myocardial remodeling.\n\nThis study aims to evaluate \\[68Ga\\]Ga-FAPI PET imaging for staging ATTR-CM and distinguishing patients with disease progression under therapy. The investigators hypothesize that \\[68Ga\\]Ga-FAPI uptake reflects fibrotic activity correlating with disease severity and progression. If validated, \\[68Ga\\]Ga-FAPI PET could serve as a novel biomarker for improved staging and personalized strategies in ATTR-CM.",[90],"Transthyretin Cardiac Amyloidosis",[92,93],"FAPI-46","staging and identifying progressing patients","NOT_YET_RECRUITING","2026-06-30",{"date":97,"type":41},"2026-07-02",{"date":99,"type":21},"2026-09",{"date":101,"type":21},"2027-10",{"name":47,"class":48},1,{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":76},"100569123","characterization-and-support-of-neurodevelopmental-disorders-associated-with-congenital-cardiac-malformations---neonatal-100569123","NCT06690151","Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal","CATAMARAN - Neonatal Cohort : Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal","CATAMARAN - NN","The inclusion criteria are as follows:\n\n* Fetus with a congenital heart defect (CHD) detected prenatally (prenatal diagnosis of the heart defect)\n* Fetus with a critical CHD defined as requiring cardiac surgery during the first three months of the infant's life\n* Parents affiliated with or beneficiaries of a social security or equivalent system\n* Parents' good understanding of the French language\n* Voluntary, informed, and written consent from both parents for themselves and the unborn child\n\nCriteria for parents\\*:\n\n\\- Biological parents \\*The inclusion of the father in the project does not limit the participation of the child (patient) in the study.\n\n\\*The father will be encouraged to participate in the project by providing a blood sample to create a trio (mother\u002Ffather\u002Finfant) for future genetic analyses.\n\nHowever, if the father is unavailable or does not consent to the collection and storage of samples for analysis (as part of the CATAMARAN study or future research projects related to biobanking), the child can still be included in the study.\n\nExclusion Criteria:\n\n* Medical termination of pregnancy considered\n* Genetic anomaly or malformative syndrome identified prior to inclusion",{"count":113,"type":21},450,"OBSERVATIONAL","Congenital heart defects (CHD), as the leading cause of birth defects, affect 12 million people globally and approximately 41,000 newborns each year in Europe. CHD presents a significant public health concern due to its association with high morbidity and mortality rates across the lifespan. Over 50% of infants born with critical CHD will develop neurodevelopmental disorders (NDD), requiring specialized care and impacting their quality of life. NDDs, involving early and persistent disruptions in cognitive, emotional, and behavioral development due to abnormal brain development, are highly variable. They may impact language, learning, motor skills, intellectual efficiency, social cognition, attention, memory, and executive functions, often accompanied by psychosocial difficulties. These hidden disabilities constitute the primary long-term sequelae of CHD, surpassing even cardiovascular complications in impact, and affect children who often undergo multiple cardiac surgeries during early childhood. NDDs are associated not only with complex CHDs but also with simpler CHDs that are repaired in early childhood and considered 'cured.'\n\nThe origin of CHD-associated NDDs remains largely unknown. While few genetic or environmental causes have been identified, recent research suggests a possible common origin linking heart malformations and neurodevelopmental abnormalities. The CATAMARAN neonatal cohort project aims to detect developmental delays associated with CHD as early as six months of age and to identify both individual susceptibility factors and acquired vulnerabilities contributing to the development of NDDs in infants with CHD.",[117,118],"Heart Disease Congenital","Neurodevelopmental Disorder",[120,121,122],"Congenital heart defects (CHD)","neurodevelopmental disorders (NDD)","genetics",{"date":124,"type":41},"2026-07-01",{"date":126,"type":41},"2025-02-28",{"date":128,"type":21},"2028-08-28",{"name":47,"class":48},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":152,"locationsCount":103},"100645418","phase-2-a-pilot-superiority-study-comparing-the-efficacy-of-a-combination-of-a-glenohumeral-intra-articular-injection-with-a-suprascapular-nerve-block-versus-a-glenohumeral-intra-articular-corticosteroid-injection-in-retractile-capsulitis-100645418","NCT07680504","A Pilot Superiority Study Comparing the Efficacy of a Combination of a Glenohumeral Intra-articular Injection With a Suprascapular Nerve Block Versus a Glenohumeral Intra-articular Corticosteroid Injection in Retractile Capsulitis","EBLOUIR","Inclusion Criteria:\n\n* Patients with shoulder pain and stiffness that has persisted for at least 2 months but less than 12 months, with a loss of passive range of motion in at least 2 planes (lateral rotation, medial rotation, abduction, forward flexion) of at least 30 degrees compared to the contralateral side\n* Patients between the ages of 18 and 65\n* Patients enrolled in a social security program\n\nExclusion Criteria:\n\n* \\- Corticosteroid injection into the affected shoulder \\\u003C 4 months ago\n* History of any surgery on the affected shoulder within the past 12 months\n* Patients with a neuromuscular condition (neurological deficit) or shoulder condition (arthropathy) that could interfere with the assessment of the primary endpoint\n* Signs or risk of infection (bacterial-like infection and\u002For fever and\u002For antibiotic use)\n* Poor skin condition of the affected shoulder\n* Anticoagulation with VKAs or anti-Xa agents, or active bleeding disorder or one in remission for less than 5 years (malignant hematologic disorders, myelodysplasia, autoimmune thrombocytopenia) or chemotherapy (antiplatelet agents permitted except prasugrel and clopidogrel)\\*\n* Uncontrolled hypertension,\n* Decompensated diabetes or diabetes at risk of decompensation,\n* Contraindications to diprosten, Kenacort, or lidocaine\n* Psychiatric conditions that may be exacerbated by corticosteroids\n* Pregnant or breastfeeding women, or women who refuse to use effective contraception\n* Individuals belonging to a vulnerable group as defined by Regulation (EU) No. 536\u002F2014 and French law (See section 4.4 of the protocol) - - Patients unable to comply with the protocol requirements (see Section 4.4 of the protocol)\n* Patients participating in another clinical research protocol involving a drug or medical device\n* Patients who refuse to participate in the study","65 Years",{"count":139,"type":21},38,[87],"Drug Trial\n\n* Single-center\n* Exploratory trial\n* Controlled\n* Randomized\n* Double-blind\n* Prospective\n\nObjective is to compare improvements in shoulder function at 3 months between the group receiving an intra-articular injection combined with a suprascapular nerve block and the group receiving an intra-articular injection combined with a placebo block 19 patients in the Experimental Group (block with corticosteroid and intra-articular injection on Day 0) 19 patients in the Control Group (block with saline and intra-articular injection on Day 0)\n\n* Total duration: 36 months\n* Recruitment period: 24 months\n* Treatment duration per patient: 2 ultrasound-guided procedures on Day 0\n* Follow-up duration per patient: 12 months after the procedure\n\nAt J0 : Under ultrasound guidance, inject 2 mL of lidocaine into the notch, then:\n\n* Experimental Group: 8 mL of 1% lidocaine into the notch with 1 mL of betamethasone,\n* Control Group: 9 mL of saline into the notch.\n\nDuring these consultations, M1, M3, M6 et M12 , the following examinations will be performed:\n\n* Clinical examination of the painful shoulder, including measurement of range of motion\n* Visual Analog Scale (VAS) for pain\n* Quick Dash, OSS, and SPADI self-report questionnaires completed by the patient\n* Recording of complications\n* Questions about returning to work",[143],"Retractile Capsulitis",[145,146],"suprascapular nerve block","intra-articular injection","2026-06-25",{"date":97,"type":41},{"date":147,"type":21},{"date":151,"type":21},"2029-06-25",{"name":47,"class":48},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":162,"conditions":163,"keywords":168,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":103},"100520649","premorbid-personality-profile-of-patients-with-cognitive-and-behavioral-disorders-100520649","NCT06059313","Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders","Relationship Between Premorbid Personality Traits and Cognitive and Behavioral Disorders","Inclusion Criteria :\n\n* Patients with behavioral variant of frontotemporal disorder (bvFTD) according to Rascovsky criteria (2011) or patients with phénocopy frontotemporal dementia (phFTD) who fulfill criteria for possible bvFTD and have no imaging abnormalities or patients with frontal variant of Alzheimer disease according to Ossenkopele criteria (2022), or patient with bipolar disorder according to CIM 10 criteria\n* Score for Mini-mental state examination ≥ 18\n* Patient with caregiver who has who has known him\u002Fher in the 10 years preceding the disease onset.\n* Patient and caregiver consents (no opposition)\n\nExclusion Criteria :\n\n* Patient with no caregiver\n* Pregnant or breast feeding women",{"count":161,"type":21},120,"Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social cognition. Symptoms vary both quantitatively and qualitatively from disease to another and from person to person. It cannot be completely excluded that in some cases, factors of susceptibility such as premorbid personality traits lead to frontal fragility.\n\nThe study will assess the relationship between premorbid profile using NEO-PI 3 inventory and cognitive and behavioral\u002Fpsychobehavioral manifestations in patients with behavioral variant of frontotemporal disorder (bvFTD), phenocopy frontotemporal dementia (phFTD), frontal variant of Alzheimer disease, bipolar disorder characterized with frontal damages.",[164,165,166,167],"Behavioral Variant of Frontotemporal Disorder (bvFTD)","Phenocopy Frontotemporal Dementia (phFTD)","Frontal Variant of Alzheimer Disease","Bipolar Disorder",[169,170,171,172],"bvFTD","fvAD","phFTD","bipolar disorder,personality",{"date":174,"type":41},"2026-06-29",{"date":176,"type":41},"2023-12-14",{"date":178,"type":21},"2026-12-14",{"name":47,"class":48},{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":207},"100622011","efficacy-of-12-week-daytime-restricted-eating-on-hepatic-steatosis-of-obesity-100622011","NCT07378072","Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity","Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity: Randomized, Open-label, Parallel Group, Controlled Superiority Trial _ CHRONOSTEATOSIS","CHRONOSTEATOSI","Inclusion Criteria:\n\n* Body mass index (BMI) between 30.0 and 49.9 kg\u002Fm2\n* Age between 18 and 65 years (limits included)\n* Sedentary (light-intensity physical activity less than 1 hour per week) or moderately active (moderate exercise 1 to 2 hours per week). Self-declared criteria.\n* Weight stable for at least 3 months prior to the beginning of the study (gain or loss \\\u003C4 kg). Self-declared criteria.\n* Able to give written informed consent\n* Self-reported eating interval \\> 12 hours per day\n* Subject who owns a smartphone with access to the internet, and agrees to use it in the study\n* Affiliation with French social security system or beneficiary from such system\n* Fibroscan® Controlled Attenuation Parameter (CAP) \\> 300 dB\u002Fms\n* Hepatitis B and C serologies negative (or showing past-infection or protective immunization)\n\nExclusion Criteria:\n\n* Alcohol intake \\> 20 g\u002Fday\n* Night-shift workers or rotating shift workers\n* Smoking\n* Patient with diabetes if HbA1c not at target (\\\u003C7%) and\u002For using a non-authorized medication)\n* Chronic liver disease other than MASLD\n* Severe hepatic disease (cirrhosis, hepatocellular carcinoma)\n* Severe cardiac disease (Chronic heart failure classified as being in New York Heart Association (NYHA) Class III or IV)\n* Severe Kidney disease with CKD-EPI\\\u003C30 mL\u002Fmin\u002F1,73m2\n* Initiation of hormonal treatment during the study period\n* Medications affecting weight or energy balance\n* Magnetic Resonance Imaging (MRI) not possible due to patient's anthropometric characteristics. Any of the following:\n\n  * abdominal and\u002For thoracic circumference with arms greater than 200 cm\n  * Sagittal diameter (or abdominal height, i.e. the distance between the dorsum and the apex of the abdomen, which was measured in the supine position at the midpoint between the iliac crest and the last rib) over 70 cm\n  * body weight over 160 kg\n* MRI not possible due to the following (an MRI safety screening form will have to be filled for inclusion): presence of a pacemaker or cardiac defibrillator or cardiovascular catheter or neurostimulator or an implantable electronic pump for automated drug injection or an electronically-controlled implantable chamber. Ocular metallic foreign bodies\n* History of severe eating disorders: Binge Eating Disorder, Bulimia Nervosa; Night eating syndrome\n* Minors\n* Adults under guardianship, trusteeship or under safeguard of justice\n* Other clinical trial participation that could interfere with the study\n* Pregnant women or women trying to be pregnant\n* Nursing mothers\n* Any treatment triggering hepatic steatosis",{"count":189,"type":21},72,[191],"NA","The objective of this study is to demonstrate that an \\\u003C or equal to 8-hour time-restricted eating (i.e., fasting for at least 16 hours every day), not focusing on reducing caloric intake, reduces intra-hepatic fat in patients with obesity and Metabolic dysfunction-Associated Steatotic liver Disease (MASLD).",[194],"MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)",[196,197,198,199],"Time-restricted eating","Obesity","MASLD","circadian rhythms","2026-06-24",{"date":174,"type":41},{"date":203,"type":41},"2026-06-17",{"date":205,"type":21},"2029-06",{"name":47,"class":48},9,{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":12,"sex":17,"minAge":215,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":218,"conditions":219,"keywords":222,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},"100640576","the-mai-foie-cohort-100640576","NCT07594990","The MAI-FOIE Cohort","Cohorte Des Maladies Auto-Immunes du Foie","AIH (Auto-Immune Hepatitis) patients :\n\nInclusion Criteria :\n\n1. age≥10 years old\n2. weight≥25kg\n3. AIH (with or without the presence of an overlap) whose diagnosis is validated by at least 2 of the following criteria :\n\n   * ALT\\>2N or IgG\\>1.1N\n   * Presence of autoantibodies : ANA (antinuclear), ML (anti-smooth muscle), SLA (anti-soluble liver antigen), LKM1 (anti-endoplasmic reticulum), LC1 (anti-liver cytosol)\n   * Presence of interface hepatitis on biopsy\n4. signing of a written consent form for participation in the study and for the storage of biological samples research\n\nControl patients :\n\n1. age≥18 years old\n2. weight≥37kg\n3. Patient with one of the following 3 conditions :\n\n   * Primary Biliary Cholangitis\n   * Metabolic steatohepatitis\n   * Drug induced hepatitis\n\nExclusion Criteria :\n\nPositive HIV serology HBV infection Positive HCV serology and PCR Patients under guardianship or curatorship","10 Years",{"count":217,"type":21},800,"The MAI-FOIE cohort will be a French multicenter cohort with the development of a biobank including patients with autoimmune, metabolic and medicated liver diseases",[220,221],"Autoimmune Liver Diseases","Immunological Mechanisms",[223,224,225,226],"Cohort","biocollection","pathophysiology","biomarkers","2026-06-23",{"date":147,"type":41},{"date":230,"type":21},"2026-06-01",{"date":232,"type":21},"2038-05-30",{"name":47,"class":48},13,{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":103},"100635388","dental-management-of-patients-with-hiv-in-pays-de-la-loire-100635388","NCT07552038","Dental Management of Patients With HIV in Pays de la Loire","Dental Management of Patients Living With HIV: A Retrospective Study Using COREVIH Data in Pays de la Loire","VIH-ODONTO","Inclusion Criteria:\n\n* Adult patients aged ≥18 years\n* Confirmed diagnosis of HIV infection\n* Followed at participating hospital centers\n* Available clinical and biological data relevant to dental care management (CD4 count, viral load, blood count)\n\nExclusion Criteria:\n\n* Patients with missing key biological data required for analysis\n* Patients not followed in participating centers\n* Patients with incomplete medical records preventing assessment of outcomes",{"count":244,"type":21},5603,"Dental care for people living with HIV has evolved with the widespread use of antiretroviral therapy, which has improved life expectancy and disease control. However, uncertainty remains about whether specific adaptations are still needed during dental procedures due to potential biological abnormalities that may increase infectious or bleeding risks.\n\nThis study aims to evaluate the proportion of patients living with HIV in the Pays de la Loire region who may require adapted dental management based on biological parameters such as immune status, hematological values, and comorbidities.\n\nA retrospective descriptive study will be conducted using anonymized data from 5,603 patients followed in the COREVIH Pays de la Loire database. The results are expected to provide objective data to better inform dental practice and reduce unnecessary precautions or stigmatization in the management of patients living with HIV.",[247,248,249],"HIV Infection","Acquired Immune Deficiency Syndrome","Oral Health Care",{"date":147,"type":41},{"date":252,"type":41},"2026-05-02",{"date":254,"type":21},"2027-05-30",{"name":47,"class":48},{"id":257,"slug":258,"hasResults":12,"nctId":259,"briefTitle":260,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":266,"conditions":267,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":103},"100635389","reproducibility-of-dental-bite-mark-overlay-analysis-using-digital-3d-models-in-adult-participants-100635389","NCT07552051","Reproducibility of Dental Bite Mark Overlay Analysis Using Digital 3D Models in Adult Participants","Reproducibility and Repeatability of Digital Overlay Techniques in Bite Mark Morphological Analysis: An Observational Study Using 3D Dental Models","OVERLAY-REPRO","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients requiring dental care including intraoral optical scan\n* Able to understand the study and provide informed consent\n* Sufficient dentition allowing usable maxillary scan\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Individuals under legal protection (guardianship or curatorship)\n* Oral conditions preventing intraoral scanning\n* Refusal to participate\n* Completely edentulous patients\n* Partially edentulous patients (\\>8 missing maxillary teeth)",{"count":265,"type":21},30,"This study aims to evaluate the reproducibility and repeatability of a standardized digital overlay protocol used in forensic odontology for bite mark analysis. Bite mark analysis methods have been increasingly questioned due to concerns about their scientific reliability. This study focuses on the methodological evaluation of an overlay generation protocol independently of biological trace interpretation.\n\nThirty adult participants requiring routine dental care involving intraoral scanning will be included. A digital impression of the maxillary dentition will be obtained using a standard intraoral scanner, which is a non-invasive and routine clinical procedure.\n\nDigital dental models will be anonymized and processed using dedicated software to generate overlays. Four operators with different levels of expertise will independently perform the overlay procedure at two separate time points.\n\nThe study will assess intra-operator repeatability and inter-operator reproducibility using quantitative 2D and 3D metrics. The objective is to determine the variability of the protocol and to contribute to the standardization and reliability of overlay-based analyses in forensic dentistry.",[268,269],"Forensic Dentistry","Bite Mark Analysis",{"date":200,"type":41},{"date":272,"type":41},"2026-04-01",{"date":274,"type":21},"2027-06",{"name":47,"class":48},{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":293,"locationsCount":103},"100635517","effectiveness-of-a-four-session-focal-shock-wave-therapy-protocol-in-women-with-vulvodynia-100635517","NCT07553715","Effectiveness of a Four-Session Focal Shock Wave Therapy Protocol in Women With Vulvodynia","Evaluation of the Effectiveness of a Four-Session Low-Intensity Focal Extracorporeal Shock Wave Therapy (LiSWT) Protocol in Women With Vulvodynia: A Retrospective Observational Cohort Study","Shock-V","Inclusion Criteria:\n\n* Female patients aged 18 years or older\n* Clinical diagnosis of vulvodynia\n* Received at least one session of low-intensity focal extracorporeal shock wave therapy in routine clinical practice\n\nExclusion Criteria:\n\n* Refusal to participate (non-opposition not obtained)\n* Inability to understand French language, preventing completion of study questionnaires",{"count":285,"type":21},50,"Vulvodynia is a chronic vulvar pain condition that can significantly affect quality of life. Low-intensity focal extracorporeal shock wave therapy has been proposed as a non-invasive therapeutic option, but real-world data remain limited.\n\nThis retrospective observational study aims to evaluate the effectiveness of a four-session focal shock wave therapy protocol in women with vulvodynia treated in routine clinical practice at a university hospital. Clinical data collected during standard care, as well as questionnaire responses, will be analyzed to assess changes in symptoms and functional outcomes following treatment.",[288],"Vulvodynia",{"date":200,"type":41},{"date":272,"type":41},{"date":292,"type":21},"2026-12-01",{"name":47,"class":48},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":22,"phases":302,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":310,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":316},"100629341","synovial-tissue-as-a-biomarker-in-the-early-management-of-osteoarthritis-100629341","NCT07473414","Synovial Tissue as a Biomarker in the Early Management of Osteoarthritis","SYNPA","Inclusion Criteria:\n\n* Diagnosis of early osteoarthritis defined by the following clinical criteria:\n\n  1. score ≤ 85% in at least two of the four categories of the KOOS questionnaire: pain, symptoms\u002Fsigns, function and quality of life;\n  2. presence of tenderness on palpation of the joint space or crepitus (clinical examination);\n  3. Kellgren and Lawrence (KL) score of 0 or 3 (X-rays).\n* Referred for therapeutic management including an intra-articular injection in the affected knee\n* Patient affiliated with a social security scheme\n* Patient able to understand the protocol and having signed an informed consent form.\n\nExclusion Criteria:\n\n* Minors\n* Adults under guardianship or trusteeship\n* Pregnant women\n* Breastfeeding women\n* Protected patients\n* Curative anticoagulation\n* Thrombocytopenia \\\u003C 50,000 platelets\u002Fmm3\n* Patients who object to participating in the study.",{"count":265,"type":21},[191],"Osteoarthritis is a common disease whose prevalence continues to increase. To date, there is no medical treatment that has proven effective, and only symptomatic treatments exist, mainly to reduce pain.\n\nArthroplasty, a costly and invasive surgical procedure, is often unavoidable in advanced stages of the disease. More than just a degenerative disease of the cartilage, osteoarthritis is now recognised as a heterogeneous disease causing multi-tissue damage of varying intensity. Synovitis plays a particularly important role in the onset and progression of osteoarthritis and has been closely correlated with radiographic severity, pain and loss of joint function. The investigators have identified several synovial histological pathotypes based on the type of synovial cell infiltrate and its distribution in samples from advanced osteoarthritis (surgical waste from prosthesis implantation). The investiogators' studies show that the presence of these pathotypes appears to be related to the clinical phenotype of patients. Analysis of synovial tissue at earlier stages of the disease is now essential to advance the understanding of the role of synovitis in osteoarthritis and its link to the clinical phenotype of patients.\n\nThe objective of this protocol is to describe the different synovial histological pathotypes present in the early stages of osteoarthritis; To this end, the investigators will establish a cohort of osteoarthritis patients with a collection of synovial tissue samples obtained by ultrasound-guided needle biopsy in an outpatient setting, a well-tolerated procedure with simple follow-up, as well as blood sampling.",[305],"Osteoarthritis",[307,308,309],"arthroplasty","synovial tissue","synovial histological pathotypes",{"date":147,"type":41},{"date":312,"type":41},"2026-05-26",{"date":314,"type":21},"2028-05-26",{"name":47,"class":48},2,{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":103},"100625500","frequency-and-intensity-of-inflammatory-relapses-in-patients-with-non-infectious-posterior-uveitis-treated-with-a-fluocinolone-acetonide-implant-100625500","NCT07423442","Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant","Frequency and Intensity of REcurrences in Non-infectious Posterior Uveitis Treated With Fluocinolone Acetonide Implant (FACi): a Multicenter Retrospective Real-world Study","FIRE","Inclusion Criteria:\n\n* Adult patients aged 18 years or older\n* Diagnosis of non-infectious uveitis with posterior segment involvement\n* Presence of uveitic macular edema or persistent posterior segment inflammation\n* Treatment with a fluocinolone acetonide intravitreal implant prior to January 2024\n\nExclusion Criteria:\n\n* Infectious uveitis\n* Refusal to participate or documented opposition to the study\n* Follow-up duration shorter than 12 months after implantation",{"count":326,"type":21},100,"Non-infectious posterior uveitis is a chronic inflammatory eye disease that can lead to irreversible retinal damage and visual impairment due to repeated inflammatory relapses.\n\nThe fluocinolone acetonide intravitreal implant is approved for the prevention of inflammatory relapses in this condition, but data from real-world clinical practice remain limited, particularly regarding the intensity of relapses over time.\n\nThis multicenter retrospective observational study aims to evaluate the frequency and intensity of inflammatory recurrences in adult patients with non-infectious posterior uveitis treated with a fluocinolone acetonide implant. Clinical and imaging data routinely collected during follow-up will be analyzed over a three-year period to better characterize long-term outcomes, treatment burden, and safety in real-life conditions.",[329,330,331],"Noninfectious Posterior Uveitis","Uveitis, Posterior","Uveitic Macular Edema",{"date":200,"type":41},{"date":334,"type":21},"2026-06",{"date":336,"type":21},"2027-01",{"name":47,"class":48},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":346,"sex":347,"minAge":348,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":352,"conditions":353,"keywords":356,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":103},"100622048","multiparametric-ultrafast-ultrasound-biomarkers-for-duchenne-and-becker-muscular-dystrophies-100622048","NCT07378553","Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies","Multiparametric Ultrafast Ultrasound Evaluation of Skeletal Muscle in Duchenne and Becker Muscular Dystrophies","INNOVAN","Inclusion Criteria:\n\n* Inclusion Criteria for patients with Duchenne Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-30 at baseline testing) previously diagnosed with Duchenne Muscular Dystrophy based on absence of dystrophin expression.\n* Inclusion Criteria for patients with Becker Muscular Dystrophy: Ambulatory and non-ambulatory males (ages 5-60 at baseline testing) previously diagnosed with Becker Muscular Dystrophy based on genetically confirmed, reduced or dysfunctional dystrophin.\n* Inclusion Criteria for Aged-matched controls: Ambulatory males (ages 5-60 years) without disease or injury to the lower and\u002For upper extremities\n\nExclusion Criteria:\n\n* Exclusion Criteria for patients with Duchenne and Becker Muscular Dystrophies:\n\nInability to undergo static exam, missing measurement site (resection\u002Famputation), neurocognitive impairment preventing informed consent\n\n* Exclusion Criteria for Age-matched controls: Any condition affecting muscle metabolism\u002Ffunction, neuromuscular disease, or injury to the lower and\u002For upper extremities in the past 5 years",true,"MALE","5 Years","60 Years",{"count":351,"type":21},60,"The purpose of this research study is to determine the potential of a multiparametric ultrasound approach to non-invasively monitor disease progression and to serve as an objective outcome measure for future clinical trials in Duchenne and Becker Muscular Dystrophies.\n\nThe investigators will compare the muscles of ambulatory or non-ambulatory boys\u002Fmen with Duchenne and Becker Dystrophies with muscles of healthy age-matched individuals of the same age and monitor disease progression in those with muscular dystrophies over a 12-month year period.\n\nThe ultrafast ultrasound technology used in this study allows the simultaneous assessment of muscle structure, mechanics and physiology, including stiffness, anisotropy, viscosity, intramuscular fat, muscle volume, and microvascular perfusion. The amount of muscle alteration measured will be related to performance in daily activities, such as walking and muscle strength, in order to identify sensitive and objective markers of disease progression.",[354,355],"Duchene Muscular Dystrophy","Becker Muscular Dystrophy",[357,355,358,359,360],"Duchenne Muscular Dystrophy","Ultrasound Imaging","Ultrafast Ultrasound","Muscle",{"date":200,"type":41},{"date":363,"type":41},"2026-03-03",{"date":365,"type":21},"2029-03-03",{"name":47,"class":48},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":375,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":103},"100625499","study-of-switching-to-aflibercept-8-mg-in-patients-with-refractory-or-dependent-exudative-age-related-macular-degeneration-100625499","NCT07423429","Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration","Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration","AFLIWEST","Inclusion Criteria:\n\n* Adults (≥18 years) with exudative (neovascular) age-related macular degeneration\n* Treated with intravitreal anti-VEGF therapy for more than 1 year\n* Switched to aflibercept 8 mg before July 31, 2025\n* Injection interval strictly less than 12 weeks prior to switch\n\nExclusion Criteria:\n\n* High myopia (axial length \\> 26 mm or spherical equivalent \\\u003C -6 diopters)\n* Angioid streaks\n* Moderate or severe diabetic retinopathy\n* History of diabetic macular edema\n* History of uveitis\n* History of retinal vein occlusion (branch or central)\n* History of pseudovitelliform macular dystrophy\n* Patient under legal guardianship or curatorship\n* Pregnant or breastfeeding women",{"count":326,"type":21},"Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections.\n\nThis multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.",[378],"Exudative Age-Related Macular Degeneration",{"date":147,"type":41},{"date":381,"type":41},"2026-02-20",{"date":383,"type":21},"2026-10-20",{"name":47,"class":48},{"id":386,"slug":387,"hasResults":12,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":391,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":393,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":396,"conditions":397,"keywords":401,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":103},"100624585","clinical-relevance-of-ultrasound-based-intramuscular-fat-infiltration-assessment-in-hospitalized-older-adults-fatus-old-100624585","NCT07411547","Clinical Relevance of Ultrasound-based Intramuscular Fat Infiltration Assessment in Hospitalized Older Adults (FATUS-OLD)","Clinical Relevance of Matrix-based Ultrasound Assessment of Intramuscular Fat Infiltration in Hospitalized Older Adults (FATUS-OLD)","FATUS-OLD","Inclusion Criteria:\n\n* Age ≥ 75 years\n* Hospitalized in rehabilitation day-hospital program\n* Written informed consent\n\nExclusion Criteria:\n\n* Moderate to severe neurocognitive disorders\n* Inability to comply with study procedures","75 Years",{"count":395,"type":21},115,"Sarcopenia in older adults is associated not only with loss of muscle mass but also with deterioration of muscle quality, particularly intramuscular fat infiltration. While muscle mass is commonly assessed, muscle quality remains insufficiently explored in routine clinical practice.\n\nThe FATUS-OLD study aims to evaluate the clinical relevance of a novel ultrasound-based multiparametric approach to assess intramuscular fat infiltration and muscle volume in hospitalized older adults undergoing rehabilitation. The main hypothesis is that higher intramuscular fat infiltration at baseline is associated with poorer recovery of physical performance at 6 months, independently of muscle volume.\n\nThis non-invasive, rapid, and radiation-free imaging approach could improve sarcopenia phenotyping and help identify new prognostic biomarkers for clinical follow-up and future interventional trials.",[398,399,400],"Physical Performance Decline in Older Adults","Sarcopenia","Muscle Fat Infiltration",[399,402,403,404,405,406,407],"Older adults","Muscle quality","Intramuscular fat","Ultrasound imaging","Physical performance","Geriatric rehabilitation",{"date":147,"type":41},{"date":410,"type":41},"2026-05-21",{"date":412,"type":21},"2028-11-21",{"name":47,"class":48},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":17,"minAge":421,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":424,"conditions":425,"keywords":427,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":103},"100619154","pilot-study-on-the-adaptation-and-tolerance-of-essilor-myopia-control-spectacle-lenses-100619154","NCT07340931","Pilot Study on the Adaptation and Tolerance of Essilor® Myopia-control Spectacle Lenses","STELLAR","Inclusion Criteria:\n\n* Patients aged 6 to 16 years with progressive myopia.\n* Spherical equivalent ≤ -0.50 D under cycloplegia and presence of at least one risk factor (age \\\u003C 10 years, progression ≥ 0.50 D\u002Fyear, axial length increase ≥ 0.2 mm\u002Fyear, high myopia ≤ -6.00 D and\u002For axial length ≥ 26 mm, both parents myopic, at least one parent highly myopic, or Asian origin).\n* Patient covered by the French social security system.\n* Patient and legal guardians providing oral non-opposition to participate in the study.\n\nExclusion Criteria:\n\n* Patients with strabismus, amblyopia, or syndromic myopia","6 Years","16 Years",{"count":285,"type":21},"This observational pilot study aims to evaluate the adaptation and tolerance of Essilor® Stellest® myopia-control spectacle lenses in children with progressive myopia. The objective is to assess real-life compliance and comfort during lens wear, as these factors are essential for long-term therapeutic adherence and overall visual health outcomes",[426],"Myopia",[428,429,430],"myopia","visual correction","compliance",{"date":200,"type":41},{"date":433,"type":41},"2026-01-20",{"date":435,"type":21},"2027-01-20",{"name":47,"class":48},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":444,"targetDuration":445,"studyType":114,"phases":4,"briefSummary":446,"conditions":447,"keywords":449,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":103},"100620171","comparison-of-the-use-of-a-perforator-flap-versus-total-skin-graft-in-the-management-of-loss-of-substance-after-resection-of-cutaneous-melanoma---pilot-study-100620171","NCT07354152","COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study","COPERGRAM1","Inclusion Criteria:\n\n* Adult men or women (≥ 18 years)\n* Patients with cutaneous melanoma of any stage (I, II, or III) according to the AJCC Cancer Staging Manual, 8th edition (2017), diagnosed prior to surgery\n* Non-closable surgical defect after margin re-excision\n\nExclusion Criteria:\n\n* Patients with microscopic or macroscopic nodal involvement when the sentinel lymph node has been removed\n* Patients with distant metastases identified on ultrasound and\u002For CT scan and\u002For PET-CT, when performed\n* Surgical contraindication to perforator flap reconstruction\n* Pregnant or breastfeeding women\n* Patients without health insurance coverage\n* Vulnerable individuals: persons deprived of liberty, under legal guardianship, or under curatorship",{"count":85,"type":21},"12 Months","Melanoma is an aggressive and potentially fatal skin cancer and was the fifth most commonly diagnosed cancer among both men and women in the United States in 2022. When detected early, cutaneous melanoma has a favorable prognosis, with a 5-year survival rate exceeding 90%. Because melanoma frequently affects younger patients, wide local excision according to international guidelines may result in substantial functional and aesthetic morbidity.\n\nReconstruction is therefore a critical component of locoregional management and should aim to optimize functional and aesthetic outcomes without compromising oncologic control. To date, no consensus exists regarding the optimal reconstructive strategy. Skin grafts are often favored for their presumed ability to facilitate early detection of local recurrence but are associated with donor-site morbidity and suboptimal morphofunctional outcomes. Flap reconstruction has been reported to improve healing time and aesthetic results; however, it is not commonly considered first-line after melanoma excision, largely due to the unsubstantiated concern that flaps may delay recurrence detection. Notably, objective data supporting this concern are lacking.\n\nOnly two retrospective studies have addressed this issue. The largest, including 165 patients, reported that perforator-based pedicled flaps achieved favorable functional and aesthetic outcomes without adversely affecting locoregional disease control. A smaller study of facial melanoma similarly found immediate reconstruction with a facial artery perforator flap to be safe and aesthetically satisfactory.\n\nIn our institution, both skin grafts and flap reconstructions are used following multidisciplinary discussion. We therefore aim to comparatively evaluate wound healing after margin re-excision and patient-reported quality of life following melanoma excision, regardless of tumor stage or location, to determine whether one reconstructive approach provides superior clinical or functional benefit in routine practice.",[448],"Stage II Cutaneous Melanoma",[450,451,452],"melanoma","skin graft","perforator flap",{"date":200,"type":41},{"date":455,"type":41},"2026-02-01",{"date":457,"type":21},"2027-05-01",{"name":47,"class":48},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":469,"conditions":470,"keywords":473,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":103},"100616940","isolation-of-pulmonary-veins-using-the-box-technique-in-patients-undergoing-sternotomy-100616940","NCT07312149","Isolation of Pulmonary Veins Using the Box Technique in Patients Undergoing Sternotomy","BoxTer : Isolation of Pulmonary Veins Using the Box Technique in Patients Undergoing Sternotomy","BoxTer","Inclusion criteria:\n\n* Patients undergoing cardiac surgery via sternotomy\n* Concomitant use of the PWI box with GeminiS during surgery\n* Adult patients\n* Patients with the following characteristics: Preoperative paroxysmal\u002Fpersistent\u002Fpermanent AF; Duration of less than 5 years; And left atrium volume \\\u003C60 ml\u002Fm2\n* Informed patient who did not object to the collection of their data for the study\n\nExclusion criteria:\n\n* Unplanned surgery (emergency)\n* History of cardiac surgery (reoperation)\n* Pregnant or breastfeeding women\n* Adults under guardianship, curatorship or judicial protection\n* Patients with a life expectancy of less than three years\n* Patients currently taking medication or using an experimental device that clinically interferes with the study's evaluation criteria and results.\n* Inability to comply with the monitoring schedule.\n* Contraindication to long-term anticoagulants",{"count":468,"type":21},200,"Atrial Fibrillation (AF) is the most common cardiac arrhythmia worldwide, affecting approximately 2.8% of the population, with prevalence increasing with age. AF is associated with significant morbidity and mortality, accounting for about 25% of ischemic strokes, 10% of cryptogenic strokes, and a 10-40% annual increase in hospital admissions due to heart failure or anticoagulant-related events.\n\nAbout 10% of patients undergoing cardiac surgery have preoperative AF. In 1986, Dr. Cox introduced the MAZE procedure, a surgical technique to isolate AF triggers. Initially involving atrial incisions, it evolved to use radiofrequency lines, significantly reducing morbidity and mortality. The MAZE procedure is now strongly recommended (Class Ia evidence) for concomitant cardiac surgery. However, nearly 85% of eligible patients-especially those undergoing closed-chest cardiac surgery-do not receive this treatment due to technical challenges and limited reproducibility of the Cox-Maze IV technique.\n\nPulmonary Vein Isolation (PVI) with posterior wall isolation (PWI-Box) has emerged as an effective alternative, offering similar outcomes to Cox-Maze IV with fewer adverse effects. Innovative devices like the GeminiS (Medtronic) enable minimally invasive, thoracoscopic PVI-PWI-Box procedures without opening the heart, even off-pump. This approach could expand the use of AF ablation during combined sternotomy surgeries, aligning with clinical guidelines.\n\nPrimary Objective: Assess the efficacy of PWI-Box using GeminiS combined with other cardiac surgeries via sternotomy.\n\nPrimary Endpoint: Recurrence rate of paroxysmal or persistent AF (per ESC definition) at 1 year postoperatively, confirmed by 24-hour Holter monitoring.",[471,472],"Atrial Fibrillation (AF)","Cardiac Surgery",[474,472,475,476],"Atrial firbrillation","PWI-Box","GeminiS",{"date":200,"type":41},{"date":479,"type":21},"2026-10-05",{"date":481,"type":21},"2032-10-05",{"name":47,"class":48},{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":17,"minAge":490,"maxAge":491,"enrollmentInfo":492,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":103},"100619448","new-simulation-care-pathway-for-paediatric-mri-preparation-100619448","NCT07344753","New Simulation Care Pathway for Paediatric MRI Preparation","20 000 Lieues Sous l'IRM - New Simulation Care Pathway for Paediatric MRI Preparation : Exploratory Descriptive Pilot Study","Inclusion criteria\n\n* Children aged 36 to 72 months scheduled to undergo an MRI scan\n* Consent obtained from the child and their parent or legal guardian\n* Patient affiliated with the social security system, CMU\n* Children who has not had an MRI since the age of 10 months Exclusion criteria\n* Children who are completely hostile to the experience.\n* Children with cognitive or behavioural disorders.\n* Children or parents\u002Fguardians who do not understand French.\n* Children coming to validate the fitting of a cochlear implant","36 Months","72 Months",{"count":493,"type":21},114,"Magnetic resonance imaging (MRI) is a common imaging procedure that is safe and non-invasive, as it relies on the use of different magnetic fields. It is the gold standard examination for a wide range of pathologies.\n\nHowever, it has many disadvantages, including the repetitive noise produced by the coils during image acquisition sequences, which can cause discomfort. The noise level often exceeds 100 dB, while the noise exposure limit for workers is set at 87 dB. There is no regulatory limit for patients. Although it is relatively loud and quite unpleasant, this noise is not harmful to health and does not amplify, contrary to the perception that one may have in the tunnel. Noise-cancelling headphones and earbuds are strongly recommended for patients to reduce any discomfort that may result. In practice, the imaging department requires all patients to wear hearing protection.\n\nOther disadvantages of MRI include confinement in a tunnel and the need to remain completely immobile for approximately six sequences, each of 2 to 5 minutes in duration.\n\nThis can be problematic, particularly for patients suffering from pain or respiratory failure, or for agitated individuals who find it difficult to remain motionless in a lying position for long periods of time.\n\nThese various issues are particularly relevant in the paediatric population, for whom MRI is the preferred imaging technique due to its safety in terms of radiation exposure.\n\nThe specific characteristics of this population require more complex patient management due to the particular constraints of MRI. Acceptance of the following four points appears to be key to its successful implementation: lying down, with the head in a tunnel, intense and repeated noises, and strict immobility for at least 30 minutes. Without these conditions, the images recorded will not provide reliable results that can be used for diagnosis.\n\nTo meet these constraints, at Nantes University Hospital, general anaesthesia was routinely administered to children aged 3 to 6 until September 2023. This ensures a 100% success rate for the examination, but it is not a trivial procedure for the child and is stressful for their parents. Since then, a light sedation protocol has been offered as part of the care pathway. This involves the child taking medication one hour and then thirty minutes before the MRI scan to calm them down until they fall asleep.\n\nUnfortunately, access to this MRI under light sedation or general anaesthesia complicates the appointment booking process, as it requires the presence of a medical team during dedicated shifts.\n\nMRI scans under light sedation are scheduled for three slots per week. At the end of 2025, the waiting time was four months for light sedation and six months for general anaesthesia.\n\nIn order to improve and speed up the care of children who need to perform an MRI scan, a specific consultation with an immersive four-module programme has been designed at Nantes University Hospital with the aim of optimising the chances of success of the examination without general anaesthesia or sedation, thereby:\n\n* Reduce waiting times for appointments, and thus reduce the period of stress for parents awaiting a diagnosis for their child.\n* Reduce the time required for the examination. Indeed, an examination under light sedation considerably lengthens the treatment time, with a sedation onset time of approximately 1.5 hours.\n* Increasing the success rate of MRI scans under light sedation following failure without sedation.\n\nThis innovative approach is based on an immersive experience in the form of a course consisting of four modules designed to help children practise four areas that can be challenging for them (immersion in a tunnel, loud noise, the constraints of specific equipment, and immobility). These modules are themed around the marine world, in line with the already approved paediatric radiology programme. It will be offered to children aged 3 to 6 with no cognitive or behavioural disorders.\n\nThe modules will be installed in a paediatric consultation room and will be used for half a day each month. When not needed, they'll be put away so the room can be used for consultations.\n\nThe aim of our pilot study is to assess the impact of this immersive journey on the success of an MRI scan without general anaesthesia or sedation.",[496],"Magnetic Resonance Imaging (MRI)",[496,498,499],"Immersive experience","Paediatric MRI",{"date":200,"type":41},{"date":502,"type":41},"2026-02-11",{"date":504,"type":21},"2028-08-15",{"name":47,"class":48},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":516,"conditions":517,"keywords":521,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":531,"locationsCount":103},"100612122","study-of-nk-cells-in-the-monitoring-of-patients-with-acute-leukemia-or-myelodysplasia-100612122","NCT07249476","Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia","ENKLA-M : Study of NK Cells in the Monitoring of Patients With Acute Leukemia or Myelodysplasia","ENKLA-M","INCLUSION CRITERIA\n\n* Adult patients diagnosed with acute myeloid leukaemia (LAM), acute lymphoblastic leukaemia (LAL) or myelodysplastic syndrome (SMD).\n* Adult patients receiving a HSC transplant.\n* Adult patients receiving or not AZA treatment after transplantation.\n* Patients who have signed a consent form.\n* Patients affiliated with a social security system. EXCLUSION CRITERIA\n* Minors,\n* Pregnant and\u002For breastfeeding women\n* Adult patients under guardianship,\n* Protected persons.",{"count":515,"type":21},55,"The aim of the ENKLA-M study is to collect samples from patients with acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), and myelodysplastic syndrome (MDS) to study the evolution of blast phenotype (NK receptor ligands and adhesion molecules) and the biology of patients' NK cells). To do this, blood and bone marrow samples will be collected from patients at diagnosis in order to characterize: (I) the phenotype of ALL and AML blasts with respect to NK receptor ligands and adhesion molecules; (II) the phenotypic profile of NK cells, (III) to further characterize the NK cell repertoire dynamics over time (day 30, day 60, day 90, 6 months, and 1 year), focusing on NK cell populations identified in healthy individuals as particularly effective against leukemia, by defining their phenotypic and transcriptomic profiles; and (IV) the impact of azacitidine (AZA) and donor lymphocyte infusions (DLI) on the biology of NK cells in transplanted patients. Clinical data and KIR\u002FHLA genetic profiles will be used to analyze all NK phenotypic and functional data, with the aim of better defining: (i) the key molecular interactions between NK cells and leukemic cells; (ii) markers of NK cell anti-leukemic efficacy during hematopoietic reconstitution; and (iii) whether AZA\u002FDLI treatment enhances the functional potential of NK cells via KIR-HLA interaction, thereby improving their effectiveness against residual disease.",[518,519,520],"Leukaemia (Acute Myeloid)","Leukaemia (Acute Lymphoblastic)","Myelodysplastic Syndrome",[522,523,524,525,526],"VIDAZA","CSH graft","haematopoietic stem cell","natural killer cells","NK Cells",{"date":200,"type":41},{"date":230,"type":21},{"date":530,"type":21},"2030-06-01",{"name":47,"class":48},{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":541,"conditions":542,"keywords":544,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":316},"100607298","study-of-a-patient-cohort-following-digestive-surgical-care-after-the-implementation-of-a-telemonitoring-and-tele-coordination-platform-for-medical-paramedical-and-social-management-100607298","NCT07186738","Study of a Patient Cohort Following Digestive Surgical Care After the Implementation of a Telemonitoring and Tele-coordination Platform for Medical, Paramedical, and Social Management","EPOCA","Inclusion Criteria:\n\n* Male or female patients over 18 years of age.\n* Patients undergoing colorectal or bariatric surgery not routinely managed as outpatient procedures at Nantes University Hospital.\n* At least one of the following criteria:\n* Anticipated early discharge (within 24 hours post-surgery) for procedures not routinely managed as outpatient at the hospital.\n* Estimated risk of readmission greater than 6% according to the Tevis et al. nomogram, adapted to the postoperative context in digestive surgery (\\>50 points on this score).\n* Patients enrolled in a health insurance plan\n\nExclusion Criteria:\n\n* Discharge to a rehabilitation center requested by the patient\n* Condition routinely managed as an outpatient procedure\n* Patient under home hospitalization care\n* Suicidal or heteroaggressive risk in a patient living alone at home\n* Homeless patients\n* Pregnant or breastfeeding women\n* Patients under legal guardianship, conservatorship, or judicial protection",{"count":540,"type":21},250,"Postoperative hospital stays and complications vary widely after digestive surgery. Enhanced Recovery After Surgery (ERAS) protocols have shortened stays and accelerated recovery after elective procedures, but they remain challenging in emergency surgery and among frail or elderly patients. While theoretical discharge after colorectal surgery is possible between postoperative days 2 and 7, average stays in practice are 12-14 days. Bariatric surgery similarly targets discharge on days 2-3, yet typical stays are 8-10 days. Patients successfully managed under ERAS may face higher readmission risk, often due to worsening comorbidities or serious complications.\n\nProlonged hospitalization and readmissions impact patient safety, comfort, and healthcare costs. Daily hospital costs in surgical units range from €350 to €400. Post-acute care facilities can reduce readmissions but often have long waiting periods. To minimize readmission risk, many surgeons prefer in-hospital postoperative monitoring, limiting early discharge.\n\nRecent studies show that connected devices and teleconsultation can provide safe and effective postoperative follow-up. Teleconsultation follow-up is feasible for most patients, with satisfaction rates comparable to in-person visits. Remote monitoring of stoma care has been associated with reduced readmissions. Home-based monitoring using connected vital sign devices in high-risk patients reduces readmissions and emergency visits. In colorectal and bariatric surgery, daily remote monitoring after early discharge (24-48 hours) did not increase morbidity or readmission, suggesting that telemonitoring can safely enable earlier discharge while maintaining patient safety. Continuous monitoring is particularly important for high-risk patients due to rapid deterioration from potential complications.\n\nEPOCA is a telemonitoring and telecoordination platform providing medical, paramedical, and social follow-up at home. It combines connected devices, a digital platform for data analysis, and a dedicated medical and paramedical team. Services include teleconsultations, home paramedical care, support for families or care facilities, and 24\u002F7 emergency management.\n\nEPOCA reassures patients and caregivers, supports primary care and home care teams, and integrates hospital and emergency services. It addresses challenges posed by aging populations, chronic disease prevalence, and increasingly complex patients. By enabling earlier discharge without increasing readmissions, EPOCA offers a holistic solution bridging hospital and home care. It has already demonstrated success in preventing hospitalizations in high-risk elderly patients and is authorized for telemonitoring of chronic conditions including diabetes, respiratory, renal, and cardiac insufficiency.\n\nThis study aims to evaluate the feasibility of implementing EPOCA over two years in the CHU Nantes digestive surgery unit. It will target patients undergoing elective or urgent colorectal or bariatric surgery who are at risk of prolonged hospitalization or readmission. High-risk scenarios include anticipated early discharge within 24 hours and patients identified as having elevated readmission risk according to predefined criteria",[543],"Telemonitoring",[545,546],"telemonitoring","digestive surgery",{"date":200,"type":41},{"date":549,"type":41},"2025-10-01",{"date":551,"type":21},"2027-10-01",{"name":47,"class":48},{"id":554,"slug":555,"hasResults":12,"nctId":556,"briefTitle":557,"officialTitle":557,"acronym":558,"eligibilityCriteria":559,"healthyVolunteers":12,"sex":17,"minAge":137,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":561,"conditions":562,"keywords":563,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":567,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":103},"100593296","evaluation-of-frailty-in-patients-with-fibrosing-interstitial-lung-diseases-prognostic-and-therapeutic-impact-100593296","NCT07004595","Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact","FRAPID","Inclusion Criteria:\n\n* Patient with fibrosing ILD according to the ATS\u002FERS\u002FJRS\u002FALAT 2022 criteria.\n* Patient aged ≥ 65 years.\n* Outpatient consultation (scheduled appointment in an outpatient clinic, day hospital, or weekly hospital stay).\n* French-speaking patient.\n* Patient who has received an information sheet explaining the study and has not expressed opposition to participating in this research.\n\nExclusion Criteria:\n\n* Patient under legal guardianship, curatorship, or judicial protection.\n* Cognitive disorders limiting the use of questionnaires.\n* Patient with a CT scan showing an early usual interstitial pneumonia (UIP) pattern according to the ATS\u002FERS\u002FJRS\u002FALAT 2022 classification.",{"count":326,"type":21},"Fibrosing interstitial lung diseases (ILDs), with idiopathic pulmonary fibrosis being the most common form, primarily affect older individuals and have a poor prognosis, with a median survival of 3 to 5 years. While antifibrotic treatments such as nintedanib and pirfenidone can slow disease progression, their efficacy is often limited by side effects, particularly in elderly patients. A comprehensive patient assessment, including evaluations of frailty and sarcopenia, could optimize care by identifying those at risk for poor outcomes or poor treatment tolerance. Frailty, characterized by reduced physiological reserves, and sarcopenia, defined as a loss of muscle mass and strength, are both associated with increased mortality and morbidity risks. Although their individual impacts on fibrosing ILDs have been documented, the combined effect of these two syndromes on patient prognosis remains unexplored, highlighting the need for further studies to guide therapeutic decision-making.",[399],[564,565,566],"Fibrosing interstitial lung diseases;","frailty","sarcopenia",{"date":200,"type":41},{"date":569,"type":41},"2025-07-20",{"date":571,"type":21},"2027-12-20",{"name":47,"class":48},{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":581,"conditions":582,"keywords":584,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":103},"100593278","ethical-issues-of-using-gene-therapy-in-the-treatment-of-amd-100593278","NCT07004361","Ethical Issues of Using Gene Therapy in the Treatment of AMD","Ethical Issues of Using Gene Therapy in the Treatment of AMD (Age-related Macular Degeneration)","Inclusion Criteria:\n\n* Patients with exsudative AMD, male female \\>18 years Patients for whom the doctor could consider gene therapy.\n\nExclusion Criteria:\n\nPatients with atrophic AMD (Age-related Macular Degeneration) Patients with other degenerative retinal diseases than AMD, Patients with with associated cognitive disorders.",{"count":265,"type":21},"The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence\u002Fnon-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.",[583],"Exudative Age-related Macular Degeneration",[585,586],"ethical","Age-related Macular Degeneration",{"date":200,"type":41},{"date":589,"type":41},"2025-07-01",{"date":591,"type":21},"2026-12",{"name":47,"class":48},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":58,"minAge":18,"maxAge":601,"enrollmentInfo":602,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":613,"leadSponsor":615,"locationsCount":103},"100579142","pilot-study-to-characterize-the-endometriosis-steroidome-and-its-link-to-endocrine-disruptors-and-vaginal-dysbiosis-100579142","NCT06820450","Pilot Study to Characterize the Endometriosis Steroidome and Its Link to Endocrine Disruptors and Vaginal Dysbiosis","STERONLINE: Steroidome and Exposome of Endometriosis Single-center Case-control Study","STERONLINE","Inclusion Criteria:\n\n* Women aged 18 to 45\n* Free, informed and written consent from the patient to participate in the study\n* Good understanding of the French language\n* Patient affiliated to or benefiting from a social security or similar scheme\n\nSpecific inclusion criteria for each group:\n\nGroup 1. Controls.\n\n* Women with no laparoscopically confirmed signs suggestive of deep endometriosis.\n* No clinico-biological criteria in favour of a diagnosis of endometriotic disease, nor any radiological signs (ultrasound or MRI) suggestive of endometriosis.\n\nGroup 2. Cases of deep endometriosis.\n\n* Newly diagnosed women (less than 12 months).\n* Severe, deep endometriotic pathology with surgical indication (clinical examination, imaging tests, pre-operative findings).\n\nExclusion Criteria:\n\n* Intercurrent diagnosis of pregnancy.\n* Presence of other hormone-dependent pathologies (e.g. breast cancer, PCOS).\n* Acute infection.","45 Years",{"count":603,"type":21},135,"Endometriosis is a systemic, steroid-dependent, inflammatory disease characterized by the growth of endometrial-like tissue outside the uterus, affecting approximately 10 % of women of childbearing age. The etiology and pathophysiology of endometriosis is not completely understood to support effective treatment and prevention strategies. Despite the steroid dependency, little is known concerning the underlying metabolism of estrogen and other tightly related steroids. Moreover, shortening the long diagnostic delays is a major priority in endometriosis research.",[606],"Endometriosis",[608,609,610],"Steroidome","exposome","LC-HRMS",{"date":200,"type":41},{"date":589,"type":41},{"date":614,"type":21},"2027-07-01",{"name":47,"class":48},""]